Mads Axelsen

2.3k citations

14 papers · 1.7k indexed · 3 hit papers · h-index 7

Impact in

Critical Care and Intensive Care Medicine top 1%
- Trauma, Hemostasis, Coagulopathy, Resuscitation
Endocrinology, Diabetes and Metabolism top 1%
- Diabetes Treatment and Management
- Diabetes Management and Research

Papers in

Endocrinology, Diabetes and Metabolism 8
- Diabetes Treatment and Management 8
- Diabetes Management and Research 3
Sensory Systems 2
- Ion Channels and Receptors 2

Co-authors: Anne Flint John E. Blundell Julie Hjerpsted Rolf Rossaint Sandro Rizoli Yoram Kluger Kenneth D Boffard Brian Warren
Journals: Diabetes Obesity and Metabolism (2 papers)Diabetes Research and Clinical Practice (2 papers)Canadian Journal of Diabetes (2 papers)BMC Cardiovascular Disorders (2 papers)Clinical Trials (1 paper)
Partner nations: Denmark United Kingdom Germany

In The Last Decade

Mads Axelsen

14 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial 2017 · 340 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 The Lancet Diabetes & Endocrinology
2017 Diabetes Obesity and Metabolism
2005 The Journal of Trauma: Injury, Infection, and Critical Care

Peers

Countries citing papers authored by Mads Axelsen

Since Specialization

Citations

This map shows the geographic impact of Mads Axelsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mads Axelsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mads Axelsen more than expected).

Fields of papers citing papers by Mads Axelsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mads Axelsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mads Axelsen. The network helps show where Mads Axelsen may publish in the future.

Co-authors

The 25 scholars most cited alongside Mads Axelsen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mads Axelsen Line = papers co-authored together Mads Axelsen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Abstract CT209: Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase I/2a trial Clinical Trials ·Peter Hillemanns, Karl Ulrich Petry, Linn Woelber, Gerd Böhmer, C. Holden, Zulfathia Nurrahmawati, Karoline W. Schjetne, Agnete B. Fredriksen, Mads Axelsen	2019	3
2	Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity Diabetes Obesity and Metabolism ·Julie Hjerpsted, Anne Flint, Ashley Brooks, Mads Axelsen, Daniela Koppold, John E. Blundell	2017	170
3	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial The Lancet Diabetes & Endocrinology ·Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou, Milivoj Piletič, Ludger Rose, Mads Axelsen, Everton Rowe, J. Hans DeVries Hit paper breakdown →	2017	340
4	Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial Diabetologia ·Christoph Kapitza, Kirsten Dahl, Jacob Jacobsen, Mads Axelsen, Anne Flint	2017	81
5	Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Diabetes Obesity and Metabolism ·John E. Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Daniela Koppold, Julie Hjerpsted Hit paper breakdown →	2017	423
6	Semaglutide Improves Postprandial Glucose and Lipid Metabolism and Delays First-Hour Gastric Emptying in Subjects with Obesity Canadian Journal of Diabetes ·J. B. BIAZZI, Julie Hjerpsted, Mads Axelsen, Ashley Brooks, Anne Flint, Daniela Koppold, John E. Blundell	2016	4
7	Semaglutide Reduces Appetite and Energy Intake, Improves Control of Eating and Provides Weight Loss in Subjects with Obesity Canadian Journal of Diabetes ·B. Argo Wibowo, John E. Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Daniela Koppold, Julie Hjerpsted	2016	3
8	The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes Diabetes Research and Clinical Practice ·Christoph Kapitza, Kirsten Dahl, Jacob Jacobsen, Mads Axelsen, BCS Fernandes, Anne Flint	2016	5
9	Semaglutide reduces appetite and energy intake, improves control of eating and provides weight loss in subjects with obesity Diabetes Research and Clinical Practice ·John E. Blundell, Graham Finlayson, Mads Axelsen, Anne Flint, Catherine Gibbons, Daniela Koppold, BCS Fernandes, Julie Hjerpsted	2016	1
10	Increased susceptibility to cardiovascular effects of dihydrocapcaicin in resuscitated rats. BMC Cardiovascular Disorders ·Keld Fosgerau, Giuseppe Ristagno, M.N. Jayatissa, Mads Axelsen, А. Н. Барсуков, U. Weber, Lars Køber, C. Torp-Pedersen, Lesia Rostyslavivna Ladiieva	2010	5
11	Increased susceptibility to cardiovascular effects of dihydrocapcaicin in resuscitated rats. Cardiovascular effects of dihydrocapsaicin BMC Cardiovascular Disorders ·Keld Fosgerau, Giuseppe Ristagno, M.N. Jayatissa, Mads Axelsen, А. Н. Барсуков, U. Weber, Lars Køber, Christian Torp‐Pedersen, 浩北林	2010	8
12	Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials The Journal of Trauma: Injury, Infection, and Critical Care ·Kenneth D Boffard, Bruno Riou, Brian Warren, Peter Choong, Sandro Rizoli, Rolf Rossaint, Mads Axelsen, Yoram Kluger Hit paper breakdown →	2005	508
13	RECOMBINANT FACTOR VIIa (NOVOSEVEN®) AS ADJUNCTIVE THERAPY FOR BLEEDING CONTROL IN TRAUMA - A RANDOMIZED, PLACEBOCONTROLLED TRIAL. Shock ·Bruno Riou, Kenneth D Boffard, B L Warren, Rafael Montanari, Yoram Kluger, Rolf Rossaint, Mads Axelsen, Sandro Rizoli, Carl J. Hauser	2004	5
14	Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin Diabetes Care ·Kjeld Hermansen, Sten Madsbad, Hans Perrild, Allan Kristensen, Mads Axelsen	2001	138

About Mads Axelsen

Mads Axelsen is a scholar working on Endocrinology, Diabetes and Metabolism, Sensory Systems, Pharmacology, Emergency Medicine and Critical Care and Intensive Care Medicine, having authored 14 papers that have together received 1.7k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (8 papers), Metabolism, Diabetes, and Cancer (7 papers), Pharmacology and Obesity Treatment (4 papers), Diabetes Management and Research (3 papers), Ion channel regulation and function (2 papers), Respiratory and Cough-Related Research (2 papers), Ion Channels and Receptors (2 papers) and Trauma and Emergency Care Studies (2 papers). The work is most often cited by research in Critical Care and Intensive Care Medicine (344 citations), Endocrinology, Diabetes and Metabolism (968 citations), Emergency Medicine (235 citations), Biochemistry (130 citations) and Pharmacology (338 citations). Mads Axelsen has collaborated with scholars based in Denmark, United Kingdom and Germany. Frequent co-authors include Anne Flint, John E. Blundell, Julie Hjerpsted, Rolf Rossaint, Sandro Rizoli, Yoram Kluger, Kenneth D Boffard, Brian Warren, Bruno Riou and Peter Choong. Their work appears in journals such as Diabetes Obesity and Metabolism, Diabetes Research and Clinical Practice, Canadian Journal of Diabetes, BMC Cardiovascular Disorders and Clinical Trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact